Tevard Biosciences is a biotechnology company focused on developing gene therapy approaches, specifically tRNA-based therapies, to cure rare genetic diseases. The organization emphasizes suppressor tRNA technologies to restore full-length proteins across multiple disease targets, including cardiac and muscular disorders, using AAV delivery and basket-style clinical strategies. Based in the United States, with leadership rooted in prominent academic and biotech backgrounds, the company aims to translate transformative genetic therapies into durable cures for patients with nonsense mutations.
No recent deals for this company.